Methotrexate-induced Transient Encephalopathy in an Adolescent and Young Adult Patient with Acute Lymphoblastic Leukemia

Teshima, Kazuaki; Kume, Masaaki; Kondo, Rui; Shibata, Kenichi; Aono, Hiroaki; Fushimi, Susumu; Takahashi, Satoshi; Takahashi, Satsuki; Saito, Masahiro; Takahashi, Naoto

doi:10.2169/internalmedicine.5937-20

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurological events occur approximately one to two weeks after MTX administration ( 4 , 7 ). Symptoms typically fluctuate and disappear completely and do not recur with MTX re-challenge treatment; however, in some cases, encephalopathy is repeated ( 14 ). The time to resolution is reported to usually be from one to seven days ( 4 , 5 , 7 ).…”

Section: Discussionmentioning

confidence: 99%

Methotrexate-induced Subacute Encephalopathy That Showed No Abnormalities on Magnetic Resonance Imaging Soon after Symptom Appearance

et al. 2023

View full text Add to dashboard Cite

A 21-year-old woman was diagnosed with acute lymphoblastic leukemia. After the administration of intrathecal methotrexate (MTX), the patient experienced dysarthria and paralysis for one hour. Magnetic resonance imaging (MRI) performed one hour from the onset and just before symptoms disappeared revealed no abnormalities. The next day, the symptoms appeared again, and diffusion-weighed MRI revealed a highintensity area in the left frontal lobe. The patient was diagnosed with MTX-induced encephalopathy. This case suggested that MRI performed as soon as symptoms appear might show normal findings in MTXinduced encephalopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Methotrexate-induced Subacute Encephalopathy That Showed No Abnormalities on Magnetic Resonance Imaging Soon after Symptom Appearance

et al. 2023

View full text Add to dashboard Cite

show abstract

Methotrexate

2021

Reactions Weekly

View full text Add to dashboard Cite

New and little-known possibilities of edaravone in the treatment of cerebral stroke and extracranial pathology

Halushko

2023

View full text Add to dashboard Cite

BACKGROUND. Edaravone is a free radical scavenger and inhibits lipid peroxidation and thus reduces oxidative damage to brain cells and other organs. Edaravone is mainly known as an effective agent in the treatment of ischemic stroke and amyotrophic lateral sclerosis. OBJECTIVE. To investigate the little-known possibilities of edaravone when it is used in clinical practice. MATERIALS AND METHODS. To solve the task, a search and analysis of full-text articles was conducted in the PubMed, Web of Science, Google Scholar, and Scopus databases. The search was conducted using the key word “edaravone” and included English-language and Ukrainian-language publications over the past 5 years (from April 2018 to April 2023). RESULTS. A total of 518 publications were identified and analyzed. Edaravone has been found to improve the clinical course and may be useful in the treatment of central nervous system diseases, depression, post-traumatic stress disorder, cognitive dysfunction, oncological and infectious diseases (in particular, coronavirus disease), many poisonings, etc. All this dictates the need for further clinical studies to explore new and unexpected possibilities of edaravone.

show abstract

Methotrexate-induced Transient Encephalopathy in an Adolescent and Young Adult Patient with Acute Lymphoblastic Leukemia

Cited by 3 publications

References 18 publications

Methotrexate-induced Subacute Encephalopathy That Showed No Abnormalities on Magnetic Resonance Imaging Soon after Symptom Appearance

Methotrexate-induced Subacute Encephalopathy That Showed No Abnormalities on Magnetic Resonance Imaging Soon after Symptom Appearance

Methotrexate

New and little-known possibilities of edaravone in the treatment of cerebral stroke and extracranial pathology

Contact Info

Product

Resources

About